🍽️ tranylcypromine hydrochloride,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Major Depressive Disorder (MDD):

    • Tranylcypromine is indicated for the treatment of major depressive disorder, also known as clinical depression. It belongs to the class of antidepressant medications known as monoamine oxidase inhibitors (MAOIs). Tranylcypromine works by inhibiting the enzyme monoamine oxidase, which results in increased levels of certain neurotransmitters such as serotonin, norepinephrine, and dopamine in the brain. This mechanism helps alleviate depressive symptoms.
  2. Atypical Depression:

    • Tranylcypromine may be particularly effective in treating atypical depression, a subtype of depression characterized by mood reactivity (positive changes in mood in response to positive events), increased appetite or weight gain, excessive sleepiness or oversleeping (hypersomnia), heaviness in the arms and legs (leaden paralysis), and a pattern of interpersonal rejection sensitivity. MAOIs like tranylcypromine have been found to be more effective than other antidepressants in some cases of atypical depression.
  3. Treatment-Resistant Depression (TRD):

    • Tranylcypromine is sometimes prescribed for individuals who have not responded adequately to other antidepressant medications, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), or tricyclic antidepressants (TCAs). It may be used as an alternative or adjunctive therapy in cases of treatment-resistant depression.
  4. Social Anxiety Disorder (SAD):

    • Tranylcypromine has been investigated for its potential efficacy in the treatment of social anxiety disorder, also known as social phobia. Some studies suggest that MAOIs may be effective in reducing social anxiety symptoms, although SSRIs are typically considered first-line treatment for this condition.
  5. Panic Disorder:

    • Tranylcypromine may also be used off-label in the treatment of panic disorder, a type of anxiety disorder characterized by recurrent and unexpected panic attacks. MAOIs have been found to be effective in reducing the frequency and severity of panic attacks in some individuals.
  6. Obsessive-Compulsive Disorder (OCD):

    • In certain cases, tranylcypromine may be prescribed off-label for the treatment of obsessive-compulsive disorder (OCD), particularly when other medications have not been effective. However, SSRIs are typically preferred as first-line treatment for OCD.
  7. Side Effects:

    • Common side effects of tranylcypromine may include dizziness, drowsiness, insomnia, headache, dry mouth, blurred vision, constipation, urinary retention, weight gain, and sexual dysfunction. More serious but rare side effects may include hypertensive crisis (dangerously high blood pressure), serotonin syndrome (potentially life-threatening condition characterized by confusion, agitation, fever, sweating, rapid heart rate, and muscle stiffness), and hepatotoxicity (liver damage).
;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations   |   βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of tranylcypromine hydrochloride,(prescription) On Probiotics

Rank Probiotic Impact
species Bifidobacterium longum Reduces
species Escherichia coli Reduces
subspecies Bifidobacterium longum subsp. infantis Reduces
subspecies Bifidobacterium longum subsp. longum Reduces

Bacteria Impacted by tranylcypromine hydrochloride,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Lacrimispora genus Decreases 👪 Source Study
Lachnospira genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Coprococcus genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Eggerthella genus Decreases 👪 Source Study
Bifidobacterium genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
Escherichia genus Decreases 👪 Source Study
Agathobacter genus Decreases 👪 Source Study
Dorea genus Decreases 👪 Source Study
Ruminococcus genus Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
Eggerthellales order Decreases ⚗️ Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O55:H7 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
Lacrimispora saccharolytica species Decreases 📓 Source Study
Lachnospira eligens species Decreases 📓 Source Study
Bacteroides xylanisolvens species Decreases 📓 Source Study
Coprococcus comes species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
[Ruminococcus] torques species Decreases 📓 Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Eggerthella lenta species Decreases 📓 Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Bifidobacterium longum species Decreases 📓 Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Roseburia hominis species Decreases 📓 Source Study
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
Agathobacter rectalis species Decreases 📓 Source Study
Dorea formicigenerans species Decreases 📓 Source Study
Ruminococcus bromii species Decreases 📓 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Bifidobacterium longum subsp. infantis subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. longum subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. suillum subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of tranylcypromine hydrochloride,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Acne 0.1 -0.1
ADHD 0.3 0.2 0.5
Age-Related Macular Degeneration and Glaucoma 0.1 0.1
Allergic Rhinitis (Hay Fever) 0.2 0.2 0
Allergies 0.3 0 0
Allergy to milk products 0.2 0.1 1
Alopecia (Hair Loss) 0 0
Alzheimer's disease 0.3 0.9 -2
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.6 0.1 5
Ankylosing spondylitis 0.2 0.4 -1
Anorexia Nervosa 0.4 -0.4
Antiphospholipid syndrome (APS) 0.1 0.1
Asthma 0.2 0.2 0
Atherosclerosis 0.1 0 0
Atrial fibrillation 0.6 0.3 1
Autism 0.8 1.2 -0.5
benign prostatic hyperplasia 0 0
Bipolar Disorder 0.2 0.3 -0.5
Brain Trauma 0.1 0.2 -1
Carcinoma 0.4 0.2 1
Celiac Disease 0.2 0.5 -1.5
Cerebral Palsy 0.1 0.2 -1
Chronic Fatigue Syndrome 0.6 0.7 -0.17
Chronic Kidney Disease 0.5 0.4 0.25
Chronic Lyme 0.2 -0.2
Chronic Obstructive Pulmonary Disease (COPD) 0.4 -0.4
Chronic Urticaria (Hives) 0.1 0.1
Coagulation / Micro clot triggering bacteria 0.1 0 0
Colorectal Cancer 0.4 0.1 3
Constipation 0.4 0 0
Coronary artery disease 0 0.1 0
COVID-19 0.8 1 -0.25
Crohn's Disease 0.6 1 -0.67
cystic fibrosis 0.1 0.3 -2
deep vein thrombosis 0.1 0 0
Depression 1.2 0.9 0.33
Dermatomyositis 0.1 -0.1
Eczema 0 0.1 0
Endometriosis 0.5 0.2 1.5
Epilepsy 0.3 0.2 0.5
Fibromyalgia 0.1 0.5 -4
Functional constipation / chronic idiopathic constipation 0.6 0.6 0
gallstone disease (gsd) 0.1 0.1 0
Generalized anxiety disorder 0.1 0.5 -4
Gout 0.1 -0.1
Graves' disease 0.2 0.1 1
Halitosis 0.2 0.2
Hashimoto's thyroiditis 0.5 0.2 1.5
Histamine Issues,Mast Cell Issue, DAO Insufficiency 0.6 0.1 5
hyperglycemia 0 0.2 0
Hyperlipidemia (High Blood Fats) 0.1 0.1
hypertension (High Blood Pressure 0.3 0.5 -0.67
Hypothyroidism 0.3 -0.3
Hypoxia 0.2 0.2
IgA nephropathy (IgAN) 0.4 -0.4
Inflammatory Bowel Disease 0.4 0.8 -1
Insomnia 0.2 0.4 -1
Intelligence 0.1 0.1
Intracranial aneurysms 0.2 0.2
Irritable Bowel Syndrome 0.4 0.4 0
Liver Cirrhosis 0.5 0.4 0.25
Long COVID 0.8 1.1 -0.38
Low bone mineral density 0.4 -0.4
Lung Cancer 0 0 0
ME/CFS with IBS 0.5 -0.5
ME/CFS without IBS 0.4 0.3 0.33
Menopause 0.1 0.1
Metabolic Syndrome 0.6 0.7 -0.17
Mood Disorders 1.3 1 0.3
Multiple Sclerosis 0.5 0.6 -0.2
Multiple system atrophy (MSA) 0.1 0.1 0
Neuropathy (all types) 0 0
neuropsychiatric disorders (PANDAS, PANS) 0.1 0.1
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0.1 0.7 -6
NonCeliac Gluten Sensitivity 0.1 -0.1
Obesity 0.8 0.4 1
obsessive-compulsive disorder 0.5 0.6 -0.2
Osteoarthritis 0.2 0 0
Osteoporosis 0.3 0.2 0.5
Parkinson's Disease 0.4 0.4 0
Polycystic ovary syndrome 0.2 0.1 1
Postural orthostatic tachycardia syndrome 0.2 -0.2
Premenstrual dysphoric disorder 0.1 0.1
primary biliary cholangitis 0 0
Psoriasis 0.2 0.3 -0.5
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 0.7 0.4 0.75
Rosacea 0.2 0 0
Schizophrenia 0.7 0.2 2.5
scoliosis 0.1 0.4 -3
Sjögren syndrome 0 0.3 0
Sleep Apnea 0.2 0.4 -1
Small Intestinal Bacterial Overgrowth (SIBO) 0.1 0.1 0
Stress / posttraumatic stress disorder 0.4 0.6 -0.5
Systemic Lupus Erythematosus 0.4 0.3 0.33
Tic Disorder 0 0.1 0
Tourette syndrome 0.2 -0.2
Type 1 Diabetes 0.3 0.2 0.5
Type 2 Diabetes 0.6 0.5 0.2
Ulcerative colitis 0.4 0.4 0
Unhealthy Ageing 0.6 0.3 1

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.